Taxifolin Attenuates Cisplatin‐Induced Acute Kidney Injury by Promoting Fatty Acid Oxidation
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Xuejin Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yongkang First People's Hospital, Hangzhou Medical College, Yongkang, China. Hauptthemen laut MEDLINE: Cisplatin, Quercetin, Acute Kidney Injury, Fatty Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: The study was supported by the General Scientific Research Project of Department of Education of Zhejiang Province (Y202456747 to Qian Zhou)..
Abstract (Originalsprache)
Cisplatin‐induced nephrotoxicity frequently manifests as acute kidney injury (AKI), creating a major limitation for its widespread clinical application. Taxifolin, a phytochemical flavonoid, possesses potent free radical‐scavenging activity and the ability to modulate inflammatory responses. Our study focused on assessing the renoprotective capacity of taxifolin in the context of cisplatin‐induced kidney damage. Cell culture studies showed that taxifolin reduced damage to human tubular epithelial cells caused by cisplatin. Furthermore, we evaluated the protective effect of taxifolin on mice with cisplatin‐induced nephrotoxicity. Oral administration of taxifolin effectively mitigated both functional impairment and structural injury in renal tubules, both when administered 2 days before and 2 h following cisplatin injection. Transcriptomic analysis of renal tissues via RNA‐seq revealed that taxifolin's nephroprotective effects against cisplatin toxicity may involve Fabp4‐regulated lipid metabolism pathways. In both cisplatin‐induced AKI mouse models and renal tubular cells, taxifolin enhanced lipid metabolism, restored cellular energy (ATP) production, and upregulated PGC‐1α/PPARα expression by reversing Fabp4‐impaired suppression of fatty acid beta‐oxidation. Collectively, these results indicate that taxifolin exerts nephroprotective effects against cisplatin‐induced AKI by modulating Fabp4‐dependent fatty acid oxidation pathways, positioning it as a potential therapeutic candidate for cisplatin‐associated nephrotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Yongkang First People's Hospital, Hangzhou Medical College, Yongkang, China.
- Zhejiang TCM Key Laboratory of Pharmacology and Translational Research of Natural Products, School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
ORCID-Profile: Guang Liang, Xiangwei Xu, Qian Zhou
Förderung
- The study was supported by the General Scientific Research Project of Department of Education of Zhejiang Province (Y202456747 to Qian Zhou).
Zitieren
APA
Jin, X., Wang, L., Yuan, M., Tao, H., Zha, H., Xu, Z., Liang, G., Xu, X., & Zhou, Q. (2025). Taxifolin Attenuates Cisplatin‐Induced Acute Kidney Injury by Promoting Fatty Acid Oxidation. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70559
Vancouver
Jin X, Wang L, Yuan M, Tao H, Zha H, Xu Z, et al. Taxifolin Attenuates Cisplatin‐Induced Acute Kidney Injury by Promoting Fatty Acid Oxidation. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70559
BibTeX
@article{Jin2025,
author = {Jin, Xuejin and Wang, Lingkun and Yuan, Miao and Tao, Huanyan and Zha, Huiyan and Xu, Zheng and Liang, Guang and Xu, Xiangwei and Zhou, Qian},
title = {Taxifolin Attenuates Cisplatin‐Induced Acute Kidney Injury by Promoting Fatty Acid Oxidation},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70559}
}
EUVIMED